WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > National Research Council Canada
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Webinar
Conference
Cell and Gene Therapy
Biocytogen | June 23, 2021
Biocytogen, a worldwide biotechnology organization zeroed in on neutralizer drug innovative work (R&D) utilizing creative genetically designed creature models, today declared the fruitful culmination of another round of financing adding up to a huge number of dollars. The financing was together finished by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was set up in 2009. Utilizing its primary quality altering innovation, th...
Industrial Impact, Medical
Willow Biosciences Inc. | December 08, 2022
Willow Biosciences Inc. a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients announced today that it has taken additional steps to focus on near-term revenue generation, protect its balance sheet and reduce its cash burn. Since the early part of the year, the Company has reviewed its market opportunities and its portfolio, using a rigorous evaluation process that has taken into consideration ...
Industrial Impact
Blue Water Ventures International | January 20, 2022
Psycheceutical, Inc. a biotechnology company dedicated to the development and commercialization of psychedelic medicines, announced the company has been fully acquired by Blue Water Ventures International, Inc. “We are thrilled that this deal has closed and that Psycheceutical is now a wholly-owned subsidiary of a publicly-listed company and has secured important near-term capital to pursue our growth plans. We will immediately begin the next steps of o...
OMass Therapeutics | February 21, 2022
OMass Therapeutics a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to confirm that it will be presenting at a number of upcoming banking, business and scientific conferences, as detailed below. “As we develop our unique drug discovery platform, OdyssION™, and progress our pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bou...
infographic
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE